Grant Revenue - Additional Information (Details) - USD ($) |
3 Months Ended | 6 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
Sep. 01, 2024 |
Sep. 19, 2022 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2025 |
Oct. 04, 2024 |
|
| Disaggregation of Revenue [Line Items] | ||||||||
| Revenue recognized | $ 411,000 | $ 1,390,000 | $ 1,439,000 | $ 2,449,000 | ||||
| CPRIT Contract [Member] | ||||||||
| Disaggregation of Revenue [Line Items] | ||||||||
| CPRIT grant | $ 17,600,000 | |||||||
| Grant funding term | 3 years | |||||||
| CPRIT grant funding term, description | The CPRIT Grant is subject to customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar for every two dollars awarded by CPRIT), revenue sharing obligations upon commercialization of rhenium (186Re) obisbemeda based on specific dollar thresholds and tiered low single digit royalty rates until CPRIT receives the aggregate amount of 400% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements. As of June 30, 2026, the Company had received approximately $15.9 million in milestone payments under the CPRIT contract. | |||||||
| Contract effective date | Aug. 31, 2022 | |||||||
| Percentage of aggregate amount of proceeds awarded under CPRIT grant | 400.00% | |||||||
| Percentage of grant proceeds with interest not exceed annually | 5.00% | |||||||
| Milestone payments | $ 15,900,000 | |||||||
| CPRIT Contract [Member] | Grant [Member] | ||||||||
| Disaggregation of Revenue [Line Items] | ||||||||
| Revenue recognized | 400,000 | $ 1,400,000 | $ 1,400,000 | $ 2,400,000 | ||||
| Grant revenue receivable | $ 1,800,000 | 1,800,000 | $ 300,000 | |||||
| Congressionally Directed Medical Research Programs [Member] | ||||||||
| Disaggregation of Revenue [Line Items] | ||||||||
| Amount to be received as award for research and development | $ 3,000,000 | |||||||
| Department of Defense Award [Member] | ||||||||
| Disaggregation of Revenue [Line Items] | ||||||||
| Grant revenue | $ 0 | |||||||
| Research and development award in period | 3 years | |||||||
| First payment received | $ 900,000 | |||||||
| X | ||||||||||
- Definition Amount to be received as award for research and development. No definition available.
|
| X | ||||||||||
- Definition Contract effective date. No definition available.
|
| X | ||||||||||
- Definition CPRIT grant funding term. No definition available.
|
| X | ||||||||||
- Definition First Payment Received No definition available.
|
| X | ||||||||||
- Definition Grant funding term. No definition available.
|
| X | ||||||||||
- Definition Milestone Payments. No definition available.
|
| X | ||||||||||
- Definition Percentage of aggregate amount of proceeds awarded under CPRIT grant. No definition available.
|
| X | ||||||||||
- Definition Percentage of grant proceeds with interest not exceed annually. No definition available.
|
| X | ||||||||||
- Definition Research and development award in period. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met. Includes, but is not limited to, government grant, assistance, incentive, award, subsidy, and loan. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|